The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | The role of red cell mass measurement in the diagnosis of polycythemia vera
Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, discusses the relevance of red cell mass measurement in the diagnosis of polycythemia vera (PV). This test quantifies the number of circulating red cells and allows to confirm the presence of polycythemia. Although its use has significantly decreased as today, patients with PV are diagnosed with a JAK2 mutation test, this test may still have a role in patients who are JAK2-negative or in patients with splanchnic vein thrombosis (SVT). This interview took place virtually.
Disclosures
Advisory boards for Novartis, Abbvie, BMS, AOP Orphan
